Terumo : "Corporate"(6.2 MB)

Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision

05 | Corporate

Fumihisa Hirose,

General Manager, Strategic Planning Dept. and CTO

Safe Harbor for Forward-Looking Statements and Use of Document

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.

Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

Terumo Corporation

Investor Relations Dept.

E-mail: [e-mail]

©TERUMO CORPORATION

2 / 17

Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision

GS26 FY22~26

Strengthen existing businesses and firmly invest in the future

FY27~31

Strengthen corporate foundation and generate solid profit from high- growth businesses

FY32~

Lead paradigm shift in medical care and make a leap toward a "New Terumo"

Company

Corporate

Strengthen existing

businesses

Establish and accelerate high-growth businesses

Explore new business opportunities (innovation)

Strengthen corporate foundation (innovation, human resources, profitability

improvement, production, ESG/CSV)

©TERUMO CORPORATION

3 / 17

Vision for the Next 10 Years

From Devices

To Solutions

Focus in solutions: The 3Ds

01

Delivery

High value-added biological access and delivery for advanced medical care

02	03
Digital	DeviceuticalsTM
Disease-based approach	Maximize drug effectiveness through
focused on improving long-term	innovative devices
patient QOL (Patient Journey)

©TERUMO CORPORATION

4 / 17

01

Delivery

High value-added biological access and delivery for advanced medical care

Penetration rate of minimally invasive therapy

60% or less

• The penetration rate of minimally invasive medicine is still low except for a few diseases
• Aspiring for a world with 100% minimally invasive therapy

Source: JAMA Surg. 2015;150(2):169-172, etc.

©TERUMO CORPORATION

Pursue vascular delivery

Deliver treatment to areas and cases that were previously difficult to reach

5 / 17

Pioneer new treatment routes including nonvascular routes

Develop new treatments through completely different routes

Treat with accuracy and precision

Use technology to pinpoint lesions for treatment